Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 53

Posts Tagged ‘congress’

Smart City Expo World Congress 2019

Posted by fidest press agency su venerdì, 22 novembre 2019

Cubic Corporation (NYSE: CUB) today announced that its Cubic Transportation Systems (CTS) business division will be exhibiting analytics capabilities for smart cities at partner Microsoft’s stand during Smart City Expo World Congress. Taking place Nov. 19-21 in Barcelona, Spain, Smart City Expo World Congress is a leading event for cities that is dedicated to creating a better future for cities and citizens worldwide.“We are a proud partner of Microsoft and are delighted to showcase how our technology integrates with Microsoft’s Azure cloud platform at Smart City Expo World Congress,” said Boris Karsch, vice president of strategy, Cubic Transportation Systems. “Through our partnership, we combine the power of technology with innovative solutions to connect governments, businesses and citizens with services that increase efficiencies, reduce costs and foster more sustainable cities.” Data Management Analytics Platform (DMAP): Cubic’s DMAP highlights mobility use cases across Barcelona including Twitter sentiment analysis to assess transit system performance, usage of bikes and stations for first mile/last mile transportation, real-time bus arrivals and traffic analytics, among other insights from open data sources in Barcelona.
In 2016, Cubic joined Microsoft CityNext, a global public sector initiative that empowers cities, businesses and citizens to reimagine their futures and cultivate vibrant communities with the use of innovative technology solutions to create opportunities for cities and their citizens.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Mobile World Congress Los Angeles 2019

Posted by fidest press agency su venerdì, 18 ottobre 2019

Pivotal Commware – the recognized pioneer of 5G platforms, systems and applications for increasing, speed, capacity and spectral efficiency – announced today the company will conduct live demonstrations of its Echo 5G products, solving key challenges for 5G wireless access at millimeter wave (mmWave) frequencies during Mobile World Congress Los Angeles at the Luxe Hotel on October 22-23, 2019. The Echo 5G Subscriber is a self-installable, on-the-window, precision beamforming repeater designed to counteract mmWave penetration, reflection, and structural shadowing losses so it can gently flood an interior with mmWave signal. Essentially, the Echo 5G acts as a portal between indoor and outdoor worlds. For fixed wireless access (FWA) providers serving homes and enterprises, the Echo 5G facilitates Gigabit speeds and introduces superior broadband choice and experience to cable and DSL end users. For 5G connected devices, the Echo 5G enables outdoor-to-indoor signal transitions so users can ubiquitously enjoy the immersive 5G experiences that only mmWave capacity can deliver.
The Echo 5G product line accomplishes this using Pivotal’s patented Holographic Beam Forming® (HBF) technology whose cost, size, weight and power consumption (C-SWaP) profile is significantly lower than phased array beamformers; specifically, an order of magnitude less cost, less than half the weight and less than one third the power consumption.
Lacking line-of-sight to the nearest 5G base station, the demonstration Echo 5G Subscriber unit will be assisted by the Echo 5G Network device, which, as an outdoor network repeater, captures and redirects mmWave signals from the 5G base station around obstacles like buildings and guides the coverage to extend the range of 5G base stations. By doing so, the Echo 5G Network reduces base station CAPEX, ongoing OPEX, siting costs and deployment time, while growing network coverage organically along with revenue.“During live 5G field trials, the Echo 5G Subscriber reliably demonstrated Gigabit+ ubiquitous connectivity indoors (residential buildings, office spaces, retail stores, stadium skyboxes), showcasing its ability to overcome the last obstacle to delivering 5G broadband access to homes and businesses with mmWave – in-building penetration,” said Brian Deutsch, CEO of Pivotal Commware. “Meanwhile, we expect Echo 5G Network to off-load the mmWave coverage burden from base stations, minimizing siting costs and deployment time while reducing CAPEX and with it, ongoing OPEX,” added Deutsch.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

28th Congress of the European Academy of Dermatology and Venereology

Posted by fidest press agency su martedì, 15 ottobre 2019

Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to severe atopic dermatitis (AD). Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to placebo. Safety data showed that both evaluated doses of abrocitinib (200mg and 100mg) were well tolerated and were consistent with a companion study (JADE MONO-2) from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program. The results were shared as a Late-Breaking presentation at the 28th Congress of the European Academy of Dermatology and Venereology (EADV) taking place October 9-13, 2019 in Madrid, Spain.The co-primary study endpoints in JADE MONO-1 were the proportion of patients who achieved an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin and two-point or greater improvement relative to baseline; and the proportion of patients who achieved at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) score. The key secondary endpoints were the proportion of patients achieving a four-point or larger reduction in itch severity measured with the pruritus numerical rating scale (NRS), and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD), a patient-reported measurement scale developed by Pfizer. Other secondary endpoints included the proportion of patients who achieved a 90% or greater change in EASI score, and the percentage change from baseline in their SCORing Atopic Dermatitis (SCORAD) response at all scheduled time points.“There is a critical need for additional treatment options for patients living with moderate to severe atopic dermatitis,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We are pleased by these findings, which together with the recently reported positive top-line results from our second Phase 3 trial, encourage us that, if approved, abrocitinib may provide the first oral, once-daily treatment option for these patients.”

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Late-Breaker Session at EADV Congress

Posted by fidest press agency su martedì, 15 ottobre 2019

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. Patients in the study treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543 met the primary efficacy endpoint with statistically significant differences (p <0.001) relative to placebo in the percentage of patients achieving a ≥ 50% relative change from baseline at 24 weeks using the Severity of Alopecia Tool (SALT). These results were presented during the 28th European Academy of Dermatology and Venereology (EADV) Annual Congress in Madrid, Spain.In the Phase 2 trial, the primary efficacy endpoint in the 12 mg twice-daily cohort was met with 58% of patients achieving a ≥ 50% relative reduction in their overall SALT score from baseline compared to 9% for placebo (p <0.001), with statistically significant separation from placebo occurring at Week 12. In the 8 mg twice-daily cohort, 47% of patients achieved the primary endpoint compared to placebo (p <0.001). For the 4 mg cohort, 21% of patients achieved a ≥ 50% relative reduction in their overall SALT score from baseline, however there was not a statistically significant difference from placebo.Data from the Patient Global Impression of Improvement scale showed 78% of the patients receiving 12 mg twice-daily and 58% of the patients receiving 8 mg twice-daily rated their alopecia areata as “much improved” or “very much improved” at Week 24. For both doses there was a statistically significant difference from placebo (p <0.001).In the Phase 2 trial, the most common (≥10%) side effects in the 12 mg CTP-543 dose group were headache, nasopharyngitis, upper respiratory tract infection and acne. One serious adverse event of facial cellulitis was reported as possibly related to treatment. After a brief dosing interruption, treatment was continued and this patient completed the trial. No thromboembolic events were reported during the trial.The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg, or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss. All patients who completed 24 weeks of treatment in the 12 mg dosing cohort had the opportunity to continue in a separate extension study to evaluate long-term safety and efficacy of CTP-543.Details from the oral presentation, entitled “CTP-543, an oral JAK inhibitor, achieves primary endpoint in Phase 2 randomized, placebo-controlled, dose ranging trial in patients with moderate-to-severe alopecia areata,” is available in the Scientific Presentations section of Concert’s website.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

European Society for Medical Oncology 2019 Congress

Posted by fidest press agency su giovedì, 3 ottobre 2019

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing immune modulators and precision therapies for solid tumor cancers, today presented updated data from the Phase 1a/1b clinical trial of FPA150 in patients with advanced solid tumors in a poster presentation at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain. The poster can be found on the Scientific Publications Page of the Five Prime Therapeutics website.The FPA150 data presented at ESMO included preliminary efficacy results from the Phase 1b monotherapy expansion portion of the study in patients preselected for B7-H4 tumor overexpression across breast, endometrial and ovarian cancers, and early safety results from the Phase 1a Keytruda® (pembrolizumab, a PD1 antibody) combination portion of the study in patients preselected for B7-H4 tumor overexpression in ovarian cancer.“B7-H4 is a novel T cell immune checkpoint and the early results from the phase 1b monotherapy portion of our FPA150 study provide the first clinical demonstration of B7-H4 as a potential therapeutic target,” said Helen Collins, Executive Vice President and Chief Medical Officer of Five Prime Therapeutics. “Based on the study results to-date, we continue to believe that the most promising opportunity for FPA150 is in combination with other therapeutic agents.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

European Society for Medical Oncology (ESMO) Congress 2019

Posted by fidest press agency su giovedì, 3 ottobre 2019

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO) Congress 2019, reinforcing the potential of Rubraca® (rucaparib) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA1/2 mutation. The data show a 43.9% confirmed objective response rate (ORR) by investigator assessment in 57 RECIST*/PCWG3** response-evaluable patients with a BRCA1/2 mutation. When assessed by independent radiological review, the response rate was similar (40.4%). In addition, a 52.0% confirmed prostate-specific antigen (PSA) response rate was observed in 98 response-evaluable patients with a BRCA1/2 mutation. Confirmed radiographic responses were durable, with 60 percent lasting 24 weeks or longer (15/25).The TRITON2 data will be used to support the filing of Clovis Oncology’s planned supplemental NDA to the Food and Drug Administration (FDA) for Rubraca in BRCA1/2-mutant advanced prostate cancer.Confirmed investigator-assessed RECIST* and PSA responses were also observed in patients with alterations in other DDR genes, including ATM, CDK12, CHEK2, PALB2, BRIP1, FANCA, and RAD51B.The median duration of follow-up (as of July 2, 2019) for patients in TRITON2 was 13.1 months (range 4.1–28.5 months) with the safety profile consistent with prior reports. The most common any-grade treatment-emergent adverse events (TEAE) >20% in the TRITON2 trial were asthenia/fatigue (55.3%), nausea (49.5%), anemia/decreased hemoglobin (37.9%), decreased appetite (27.9%), transient increased aspartate transaminase/alanine aminotransferase (ALT/AST) (24.7%), constipation (24.7%), vomiting (22.1%) and diarrhea (21.1%).Clovis Oncology is further evaluating the potential of Rubraca to treat advanced prostate cancer in the TRITON3 clinical trial – a multicenter, randomized, open-label Phase 3 study of Rubraca versus physician’s choice of therapy – for patients with mCRPC. TRITON3 is currently enrolling patients with BRCA1/2-mutant and ATM-mutant (both inclusive of germline and somatic) tumors with a primary objective of assessing radiographic progression-free survival (PFS) in these patients.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

International Congress of Parkinson’s

Posted by fidest press agency su sabato, 21 settembre 2019

Nice, France September 22-26, 2019 The data include two posters, which will be presented on Tuesday, September 24, 2019 from 1:45 PM to 3:15 PM CEST:Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)(Abstract #1035)
Impact of OFF periods on aspects of employment for people with Parkinson’s disease(Abstract #905)Acorda and other industry sponsors are members of The Michael J. Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the “Financial and Social Impact of Parkinson’s Disease Survey.” Results of the survey were also presented at the 5th World Parkinson Congress in June 2019.Acorda will also host a Corporate Therapeutics Symposium, “Rethinking the Approach to Managing OFF Periods,” on Tuesday, September 24 from 12:45 PM to 1:45 PM CEST in the Nice Acropolis Convention Centre. The symposium will be led by Peter LeWitt, M.D., M.Med.Sc., Director of the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital, Fernando Pagan, M.D., Professor and Vice Chairman for the Department of Neurology at MedStar Georgetown University Hospital, and Mark Lew, M.D., Professor of Clinical Neurology at the Keck School of Medicine of the University of Southern California.
Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Congress of the Council of Europe

Posted by fidest press agency su venerdì, 14 giugno 2019

Bruxelles. The European Committee of the Regions and the Council of Europe’s Congress of Local and Regional Authorities both celebrate their 25th anniversary this year. To mark the occasion, a ceremony will be held in the European Parliament during the European Committee of the Regions’ June plenary session. Committee president Karl-Heinz Lambertz and Congress president Anders Knape will both address the audience on this occasion.
The ceremony will be followed later in the day by a joint conference at the Committee of the Regions on “The added value of local and regional authorities in building a united Europe”. The aim is to highlight the synergies between the work of the two institutions with a view to strengthening local self-government and regional democracy, a priority common to the committee and the congress.The conference will consist of two discussion panels on decentralisation and the state of local and regional democracy, as well as its practical implementation in the Member States, based on the example of the fight against climate change.The Congress of Local and Regional Authorities of the Council of Europe and the European Committee of the Regions have signed a cooperation agreement that formalises the fields and methods of cooperation between the two institutions. This agreement, signed in 2005 and revised in 2018, forms part of the wider context of the 2007 Memorandum of Understanding between the European Union and the Council of Europe.

Posted in Estero/world news, Politica/Politics | Contrassegnato da tag: , | Leave a Comment »

World Organ-on-a-Chip Congress

Posted by fidest press agency su mercoledì, 12 giugno 2019

San Diego, CA, United States – October 14-15, 2019 Organ-on-a-Chip World Congress 2019 focuses on an important and expanding field wherein cells are being assembled using Microfluidics and Lab-on-a-Chip technologies in a functionally-relevant manner. These clusters of “assembled cells” have functional significance and can mimic in vivo organ structure.Liver cells assembled onboard chips in a physiologically-relevant architecture using microfluidics can, for instance, be utilized for toxicity screening and the ability to assemble organ fragments ex vivo can provide an exquisite means to reconstruct biological processes (both physiological and pathological) “in a dish” or “on a chip.”
A number of chips such as Lung-on-a-Chip, Brain-on-a-Chip, Gut-on-a-Chip, Marrow-on-a-Chip, Bone-on-a-Chip, Nerve-on-a-Chip amongst others have been built and will be presented and explored at this conference. We will also focus on “disease-on-a-chip”, cancer-on-a-chip, immune system-on-a-chip.The Conference Tracks are Co-Located and Concurrent and Delegates can Participate, Mix-and-Match Presentations and Network Extensively with their Colleagues from all 3 Conference Tracks. The Exhibit Hall is also co-located and accessible by delegates from all 3 conference tracks.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

5th World Parkinson Congress

Posted by fidest press agency su mercoledì, 5 giugno 2019

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that it will debut an art gallery inspired by people with Parkinson’s (PwP) at the 5th World Parkinson Congress (WPC) in Kyoto, Japan. The six pieces of art, ranging from acrylic sculptures to oil paintings, are the centerpiece of Acorda’s Framing OFF Through Art initiative. OFF periods are the re-emergence of Parkinson’s symptoms, and affect approximately 40 percent of the one million people living with Parkinson’s in the U.S. This initiative builds on Acorda’s “Live Well. Do Tell.℠” program; its goal is to help initiate effective conversations about OFF periods between PwPs and their healthcare professionals.Framing OFF Through Art uses the power of art to help PwPs better identify and articulate their experiences with OFF periods. It includes a series of artworks inspired by the personal stories of people with Parkinson’s and their care partners. The artworks were created by artists who also have a personal connection to the disease. Conference attendees can view the gallery and learn more at Acorda’s booth, #209.
In addition, new research on the nature and diversity of Parkinson’s disease will be presented by Connie Marras, M.D., Ph.D., associate professor at University Health Network, University of Toronto, during the Morning Plenary on June 6, 2019, at 9:30 am JST. Dr. Marras will also be presenting research around OFF periods during the poster tour on June 5, 2019. The research on OFF periods was supported by an Acorda Therapeutics research grant, administered by The Michael J. Fox Foundation for Parkinson’s Research.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

87th European Atherosclerosis Society Congress

Posted by fidest press agency su mercoledì, 29 maggio 2019

The Medicines Company (NASDAQ: MDCO) today announced presentation of analyses of two clinical studies of inclisiran at the 87th European Atherosclerosis Society (EAS) Congress in Maastricht, Netherlands. A combined analysis (N=279) from the Phase 2 ORION-1 and Phase 1 ORION-7 trials, presented during an e-poster session, demonstrated that patients across a range of renal function levels achieved consistent reductions in low-density lipoprotein cholesterol (LDL-C) with no dose adjustment necessary for patients with renal impairment. Results from the Phase 2 ORION-2 pilot study, presented as a late-breaking abstract, showed that inclisiran provided durable reductions in LDL-C levels up to day 180 in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high levels of LDL-C and early onset of cardiovascular disease, without the need to increase the dose of inclisiran.“The information discussed at EAS supports inclisiran’s potential to address the high burden of cardiovascular disease caused by cumulative exposure to elevated LDL-C,” said Peter Wijngaard, Ph.D., Chief Development Officer of The Medicines Company. “We are pleased with these findings that demonstrate inclisiran’s potent, durable and consistent lowering of LDL-C, as well as favorable tolerability and safety, in patients with renal insufficiency or HoFH.”Inclisiran, the first cholesterol-lowering therapy in the siRNA class, is The Medicines Company’s investigational therapy in Phase 3 clinical development to evaluate its ability to lower LDL-C through twice-a-year dosing. The company expects pivotal Phase 3 data readouts for inclisiran in the third quarter of 2019 followed by anticipated regulatory filings in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.“There remains significant unmet need in the treatment of ASCVD, as approximately four out of five statin-treated patients are not at LDL-C goals, with poor adherence to therapy a major underlying cause,” said Mark Timney, Chief Executive Officer of The Medicines Company. “We are excited at the prospect of bringing forward a revolutionary approach to treat cardiovascular disease using a twice-a-year therapy with unique potential to address the need for additional LDL-C lowering and long-standing medication adherence challenges faced by millions of people.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

24th World Congress of Dermatology

Posted by fidest press agency su mercoledì, 22 maggio 2019

Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24th World Congress of Dermatology (WCD). This meeting will be held in Milan, Italy from June 10-15, 2019.
Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients with vitiligo, which will be highlighted during the late-breaking research session, and 12-week data from a Phase 2 study of ruxolitinib cream in adult patients with atopic dermatitis.“We look forward to sharing initial results from our Phase 2 study of ruxolitinib cream in vitiligo and additional data from our Phase 2 trial in atopic dermatitis – two conditions for which many patients need novel and effective treatment options,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Incyte is committed to developing therapies to address key unmet medical needs, and data to be presented at WCD demonstrate exciting progress in the development of ruxolitinib cream, our most advanced inflammation and autoimmunity program.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Global Biotechnology Congress 2019

Posted by fidest press agency su mercoledì, 22 maggio 2019

The Global Biotechnology Congress (GBC 2019) in the USA will welcome distinguished Nobel laureates, speakers, delegates, biotechnologists and pharmaceutical industry leaders, from around the world.This event will focus on various important disciplines of biotechnology and its applications for improvement in health and quality of life the world over. It is anticipated that up to 1000 of the world’s leading scientists, researchers, industrialists and academicians, including several Nobel Laureates, in the fields of biotechnology and medical and biological sciences, will attend this forum, in Boston, to share and discuss new scientific ideas, products and breakthroughs. We are indeed pleased to host such an international conference in the United States of America.This conference will have a variety of lectures from eminent scientists, including Noble Laureates, who will deliver lectures on plant and environmental technologies, transgenic plants and crops, bioremediation, microbial diversity and bio-monitoring. Focus will be given to medical biotechnology, stem cells, gene therapy, tissue engineering, bio-pharmaceutical manufacturing, cell based therapy, cell cultivation, diagnostics, imaging, pharmacogenomics, microarray technology, biomarkers, pharmaceutical biotechnology, vaccines, CNS, Cancer, antibodies, protein engineering. There will also be important lectures on food, marine, bio-safety systems biology, clinical reserved/clinical trials, bioethics and Nano biotechnology.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

20th Annual International Lung Cancer Congress

Posted by fidest press agency su mercoledì, 8 maggio 2019

Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education, will host the 20th Annual International Lung Cancer Congress® from July 25 to 27 at the Huntington Regency Huntington Beach in California. The program will be chaired by Dr. David R. Gandara, professor of medicine in the division of hematology/oncology at the University of California (UC) at Davis School of Medicine and the director of the thoracic oncology program and senior adviser to the director at UC Davis Comprehensive Cancer Center, and Dr. Roy S. Herbst, Ensign professor of medicine (medical oncology), professor of pharmacology, chief of medical oncology and associate director for translational research at Yale Cancer Center, Yale School of Medicine.
The 20th Annual International Lung Cancer Congress® is a three-day program for surgical, medical and radiation oncologists interested in the treatment of patients with lung cancer. During this meeting, leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery and radiation oncology in the clinic through a series of cutting-edge lectures, panel discussions, multidisciplinary tumor boards and interactive Q&A sessions. Attendees who participate will have the opportunity to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

9th Congress of the Asia Pacific Initiative on Reproduction

Posted by fidest press agency su martedì, 7 maggio 2019

More than 1,700 fertility specialists from 50 countries are attending the 9th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2019) in Hong Kong to explore the latest advances in scientific research and clinical care of people experiencing infertility.It is one of the most influential meetings on assisted reproduction ever presented in the Asia Pacific region that is home to about 60 per cent of the world’s population.ASPIRE President, Professor Budi Wiweko, a leader in the advancement of IVF and associated technologies in the region, said outcomes from the congress would empower the region and help shape the future of assisted conception throughout the world.
People attending the congress at the Hong Kong Convention and Exhibition Centre include scientists, clinicians, embryologists, nurses and fertility counsellors to discuss and dissect future aspects of reproductive medicine.One in six couples throughout the world experience infertility, which is defined as the failure to conceive after a year of unprotected intercourse, or the inability to carry pregnancies to a live birth. The causes of infertility are equally shared between male and female partners.The World Health Organisation has forecast that infertility will become the third most serious condition after cancer and cardiovascular diseases in the 21st century.
Delegates at the ASPIRE 2019 Congress have come from across the Asia Pacific, Europe, the United Kingdom, Middle East, India, Pakistan, Australia, New Zealand, North America, South America and Canada.Professor Wiweko said ASPIRE’s widening scientific exchange with leaders in reproductive medicine in other countries would be vital in addressing a disturbing decline in fertility rates across the world, and especially in the Asia Pacific region.
There are many complex factors contributing to this trend including couples marrying later in life, growing urbanisation and associated stress levels, work pressures and environmental conditions.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

World Jewish Congress appeals to UN Security Council to condemn Hamas following barrage of hundreds of rockets against civilian areas in Israel

Posted by fidest press agency su lunedì, 6 maggio 2019

After a barrage of hundreds of rockets struck Israel from the Gaza Strip on Saturday, the World Jewish Congress appealed to Indonesia, as president of the United Nations Security Council, to lead the international community in unequivocally condemning Hamas and holding it responsible for the terrorist acts that it continues to carry out and enable in the territory under its control.In a letter to Amb. Dian Triansyah Djani, Permanent Representative of Indonesia to the United Nations, WJC CEO and Executive Vice President Robert Singer noted that the latest barrage targeted civilian areas with direct hits.“Yet again, Hamas and other terror groups in Gaza continue to indiscriminately target Israeli civilians whose sole goal is to live in peace with their neighbors. This latest provocation is simply unacceptable and unjustifiable. It is an ill-fated attempt by the group to divert attention from their mismanagement and tyrannical rule over the Palestinian people living in the Gaza Strip,” Singer wrote.“Upon taking the presidency of the UN Security Council this month, you noted that you wish to ‘keep the momentum’ in the Council on the issue of Palestine, which you will do by hosting a special Arria-Formula meeting on Monday, May 6,” Singer added.“In this meeting, it is time that the UN Security Council, its members, and the international community, unequivocally condemn Hamas and these dangerous actions, and hold Hamas responsible for the terrorist acts that it continues to carry out and enable in the territory under its control in the Gaza Strip,” Singer wrote.Over the course of Saturday, nearly 300 rockets were launched at Israel. A man was killed in Ashkelon after a rocket struck his home.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

International Liver Congress™ 2019

Posted by fidest press agency su sabato, 6 aprile 2019

Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter “Shionogi”), announced it will present four posters on lusutrombopag, a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The International Liver Congress™, the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 10-14, 2019. Lusutrombopag was granted marketing authorisation by the European Commission (EC) on February 18, 2019 for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing invasive procedures. It has already been approved for use in Japan1 and the US where it is marketed under the brand name Mulpleta®2.All poster presentations will be displayed in Reed Messe Wien Exhibition & Congress Center Hall B on Saturday, April 13, 2019 from 9:00 am to 5:00 pm Central European Time (CET). The research will be presented in the Cirrhosis and Complications poster area and will include the following: Poster SAT 002: Lusutrombopag Is a Safe Treatment Option for Thrombocytopenia in Patients with Chronic Liver Disease Undergoing an Invasive Procedure: Pooled Safety Analysis from 3 Studies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Mobile World Congress 2019

Posted by fidest press agency su sabato, 23 febbraio 2019

Barcelona 25th of February from 01:00 to 02:30pm. Venue FIBOCOM: Hall 1. Stand 1E21.FIA is built as a collaboration with operators and partners to focus on new innovations and IoT devices born from the advances of 5G connectivity. With a strong background in IoT through support from Fibocom Wireless Inc., Fibocom is the first wireless communication module and solution provider listed publicly in China(SHE: 300638). For over 20 years, Fibocom has been dedicated to providing many global top 500 IoT consumer electronics, and global carrier companies with end-to-end wireless communication solutions covering 5G, LTE, NB-IoT/eMTC, HSPA+, and GSM/ GPRS. This strong background is further enabled by the world’s largest PC parts/CPU manufacturer, and major Fibocom shareholder, Intel.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Intel at Mobile World Congress 2019

Posted by fidest press agency su domenica, 3 febbraio 2019

Barcelona Feb. 25-28 Fira Gran Via, Hall 3, Intel Booth 3E31 At Mobile World Congress 2019, Intel will demonstrate solutions powering the 5G future. Come experience compelling use cases highlighting the power of 5G across client, cloud, network and edge, enabling Intel customers to deliver new innovative capabilities and scalable and efficient business models. As the world moves beyond connecting billions of humans to connecting billions of “things,” Intel’s world-class data-centric technologies and solutions will drive 5G’s usefulness and presence everywhere.
See how delivering 5G’s expanded capacity in a manufacturing setting will enable safer, more flexible and more efficient production by applying machine-to-machine connectivity, transformed networks, computer vision, edge computing and AI capabilities to real-world applications.
Learn how edge computing will enable new revenue-generating, immersive media experiences (virtual reality/augmented reality gaming) for consumers anywhere, without being tethered to a wired network. See how Hollywood is embracing the power of Intel processing and software and the visual cloud to bring its latest films to life.
5G’s gigabit speeds, transformed networks and edge computing augmented by new computer vision and AI technologies will give retailers new capabilities to efficiently enable retail deployments in virtually any location without the expense of a wired infrastructure.
See the latest Intel partner ecosystem offerings in network, edge, vRAN and base station technology – enabled by Intel® Xeon® Scalable processors, Intel® FPGAs, Intel Atom® processors, and Intel connectivity products.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

World Jewish Congress’ 2019

Posted by fidest press agency su lunedì, 7 gennaio 2019

New York, NY – The World Jewish Congress launches today its annual WeRemember campaign, to combat anti-Semitism and all forms of hatred, genocide and xenophobia. The campaign, which runs January 6-27, will take off simultaneously in 50 countries, in 20 languages, with a number of partners including several social media giants and the United Nations Educational, Scientific, and Educational Organization (UNESCO).
The 2019 WeRemember initiative, now in its third year, urges people around the world to photograph themselves holding a #WeRemember sign and post it to social media, to spread the message that never again must mean never again. Last year, the campaign reached more than 650 million people – more than one out of 11 people worldwide.
Participant photos, interviews with Holocaust survivors, and messages from influencers of varied backgrounds, professions, ages and religions will be projected on the walls of Auschwitz-Birkenau and live streamed from January 24-27. The campaign is being held in advance of International Holocaust Remembrance Day on January 27, the anniversary of the liberation of the Auschwitz-Birkenau Nazi death camp in 1945.Social media companies, including Twitter and Snapchat, will support the World Jewish Congress’ campaign in various ways. On Snapchat, for example, the Our Story coverage of the day, including content related to Holocaust education, will be available on the Discover page on 27 January 27. Snapchatters can join the conversation by submitting their Snaps to the public Our Story using the available Filters.
The United Nations Educational, Scientific, and Cultural Organization (UNESCO) has also joined the WJC as an integral partner, after launching together a joint website on Holocaust education ( Roberta Grossman and Nancy Spielberg, the filmmakers of Who Will Write Our History, and their distributor Abramorama, are supporting the We Remember project during the global event screening in over 200 venues around the globe.The campaign will launch with a unique call by a number of Holocaust survivors who have a mission to educate the world to create a better future, and to share their stories with younger generations. These survivors include, inter alia, Toby Levy, a social media activist who has dedicated her life to educating the next generation about the danger of hatred, and Saul Dreier, the founder of the Holocaust Survivor Band and an advocate for using music as a form of remembrance. Participants amplifying the 2019 initiative also include reformed neo-Nazis, sports teams and association and people of all religions and backgrounds.
Previous campaign participants include: Pope Francis, United Nations Secretary General António Guterres, First Lady Melania Trump, Prime Minister of Israel Benjamin Netanyahu, Prime Minister of Belgium Charles Michel, Former U.S. Ambassador to the United Nations Nikki Haley, Senator of New York Charles Schumer, actress Gal Gadot, Foreign Minister of Russia Sergey Lavrov, Former Minister for Foreign Affairs of Germany Sigmar Gabriel, Holocaust survivors, and supporters from all walks of life fighting rampant antisemitism.

Posted in Estero/world news, Spazio aperto/open space | Contrassegnato da tag: , | Leave a Comment »